IMCR vs NRIX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IMCR · Immunocore$26.41 ▼ 0.83%
NRIX · Nurix Therapeutics$12.85 ▼ 5.51%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IMCR -31.7%
- NRIX -25.1%
Head to head
| Metric | IMCR | NRIX |
|---|---|---|
| Price | $26.41 | $12.85 |
| Change today | ▼ 0.83% | ▼ 5.51% |
| Market cap | $1.36B | $1.40B |
| Return, 3 months | -27.9% | -51.1% |
| Return, year to date | -23.9% | -32.3% |
| Return, 1 year | -32.9% | -23.3% |
| P/E (TTM) | – | 5.3 |
| P/B | 3.3 | 1.4 |
| P/E percentile vs own 5y | 44th | 98th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -1.4% | +8,426.3% |
| Net profit growth (YoY) | -7,935.0% | +736.2% |
| Gross margin | 98.9% | – |
| Operating margin | -6.8% | 41.3% |
| Net margin | -7.5% | 42.0% |
| Return on equity | -7.9% | 44.0% |
| Analyst target vs. price | +115.1% | +174.9% |
| Analyst buy share | 60% | 100% |
| RSI (14) | 33 | 21 |
| 30-day volatility | 53.9% | 149.6% |
| Max drawdown, 1 year | -34.3% | -53.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NRIX is the largest of the group by market value.
- NRIX has returned the most over the past year.
- NRIX is growing revenue fastest.
- NRIX keeps the most profit per dollar of sales.
- IMCR has been the calmest stock over the last 30 days.